Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107,809,066
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
24,300,186
-
Shares change
-
+6,813,778
-
Total reported value, excl. options
-
$467,047,800
-
Value change
-
+$127,200,241
-
Put/Call ratio
-
75%
-
Number of buys
-
74
-
Number of sells
-
-26
-
Price
-
$19.22
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q4 2017
132 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2017.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24,300,186 shares
of 107,809,066 outstanding shares and own 23% of the company stock.
Largest 10 shareholders include FMR LLC (4,286,578 shares), Atlas Venture Associates IX, LLC (3,579,788 shares), ORBIMED ADVISORS LLC (2,337,684 shares), Vanguard Group Inc (1,836,481 shares), BlackRock Inc. (1,710,947 shares), ARK Investment Management LLC (1,375,149 shares), STATE STREET CORP (1,155,070 shares), BAKER BROS. ADVISORS LP (1,145,453 shares), FARALLON CAPITAL MANAGEMENT LLC (1,140,000 shares), and Temasek Holdings (Private) Ltd (790,527 shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.